Evidence map›Paper›PMID 40001315›Full record

ArticleGeriatrics & gerontology international2025

Impacts of tirzepatide on older patients with diminished β-cell function and dementia.

Toshitaka Sawamura, Shigehiro Karashima, Ai Ohmori, Mitsuhiro Kometani, Takashi Yoneda

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Geriatrics & gerontology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Toshitaka SawamuraDepartment of Internal Medicine, Asanogawa General Hospital, Kanazawa, Japan.ORCID https://orcid.org/0000-0003-1279-4947
Shigehiro KarashimaDepartment of Health Promotion and Medicine of the Future, Kanazawa University, Kanazawa, Japan.
Ai OhmoriDepartment of Internal Medicine, Asanogawa General Hospital, Kanazawa, Japan.
Mitsuhiro KometaniDepartment of Health Promotion and Medicine of the Future, Kanazawa University, Kanazawa, Japan.
Takashi YonedaDepartment of Health Promotion and Medicine of the Future, Kanazawa University, Kanazawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tirzepatide could control postprandial hyperglycemia even in cases with diminished β-cell function. This finding gives new insight into the treatment of older patients with diabetes. However, tilzepatide does not replace basal insulin in cases with diminished β-cell function and requires careful observation for sarcopenia.

Indexed as

DementiaDiabetes Mellitus, Type 2HyperglycemiaHypoglycemic AgentsInsulinInsulin-Secreting CellsAgedAged, 80 and overBlood GlucoseFemaleHumansMaleTirzepatideBlood GlucoseHypoglycemic AgentsInsulinTirzepatide

Identifiers

PMID40001315
PMCPMC11973003

What Socratic holds

Texttitle and abstract
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.